

Roche Pharma Day 2021

14 September 2021



Roche Pharma Day 2021

Welcome

Karl Mahler | Head of Investor Relations

Agenda

Welcome

Karl Mahler, Head of Investor Relations

Pharma Strategy: Sustainable growth by delivering more patient benefits at reduced cost to society

Bill Anderson, CEO Roche Pharmaceuticals

Commercial Opportunities: Near-term growth drivers

Teresa Graham, Head Pharma Global Product Strategy (GPS)

Short break

Late Stage Pipeline Oncology & Non-malignant Hematology

Levi Garraway, Chief Medical Officer and Head Global Product Development

Late Stage Pipeline Neuroscience & Immunology

Global Head Neuroscience, Immunology, Ophthalmology, Infectious and Rare Diseases, Clinical Development

Late Stage Pipeline Ophthalmology


Nilesh Metha, Lifecycle Leader faricimab, GPS

Late Stage Pipeline Infectious Diseases

Barry Clinch, Global Head Infectious Diseases, Clinical Development

Q&A

Strong portfolio rejuvenation and diversification



Source: Pharma HY sales as reported in HY reports; AHR=Avastin, Herceptin, MabThera/Rituxan
 Note: HY 2011 - Inflammation/Autoimmune/Transplantation shown as Immunology and Virology shown as Infectious diseases


38 Breakthrough Therapy Designations received since 2013

Innovation driving portfolio value

Year	Molecule	Indication
2021	Venclexta + azacitidine	higher-risk MDS
	tiragolumab + Tecentriq	1L PD-L1+ NSCLC
2020	mosunetuzumab	3L+ FL
	Tecentriq	unresectable or metastatic ASPS
	Esbriet	uILD
2019	Gavreto	RET fusion-positive NSCLC
	Gavreto	RET mutation-positive MTC
	Cotellic	Histiocytic neoplasms
	Gazyva	Lupus nephritis
	rhPentraxin-2 (PRM-151)	IPF
	Venclexta + Gazyva	1L unfit CLL
	Kadcyla	Adjuvant HER2+ BC
2018	SPK-8011	Hemophilia A
	Enspryng	NMOSD
	Xolair	Food allergies
	Tecentriq + Avastin	1L HCC
	Hemlibra	Hemophilia A non-inhibitors
	Rozlytrek	NTRK+ solid tumors
2017	Polivy + BR	R/R DLBCL
	Venclexta + LDAC	1L unfit AML
	Zelboraf	BRAF-mutated ECD
	Rituxan	Pemphigus vulgaris

Source: Evaluate Vantage; July 14, 2021

Making a novel contribution (external view)



Doing now what patients need next